Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

News

Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice

One of the at-home ketamine industry’s biggest boosters has turned bearish, calling for caution among patients and providers and withdrawing his endorsement of the practice.

“After being at the forefront of at-home ketamine treatment, recent findings, like the case study of unintentional overdose via telehealth have led me to reevaluate,” said Juan Pablo Cappello, who founded at-home ketamine company Nue Life Health.

Here, we take a closer look at the case study that changed Cappello’s mind as well as broader concerns around at-home ketamine operators, and we speak with Cappello himself...

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200
  • Regular Bulletins featuring news, analysis, and research
  • Articles and deep dives across psychedelic drug development, policy, and research
  • Exclusive interviews with researchers, executives, and policymakers
  • Bespoke resources and tools including the Psychedelic Bill Tracker
  • Quarterly video briefings and slide decks

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.